Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review | Zendy

Kenneth M. Borow | Zendy; R. Preston Mason | Zendy; Krishnaswami Vijayaraghavan | Zendy

Open Access

Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review

Author(s) -

Kenneth M. Borow,

R. Preston Mason,

Krishnaswami Vijayaraghavan

Publication year - 2017

Publication title -

cardiorenal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.661

H-Index - 21

eISSN - 1664-3828

pISSN - 1664-5502

DOI - 10.1159/000479391

Subject(s) - hemodialysis , medicine , eicosapentaenoic acid , population , proinflammatory cytokine , polyunsaturated fatty acid , end stage renal disease , gastroenterology , omega 3 fatty acid , kidney disease , endocrinology , fatty acid , inflammation , docosahexaenoic acid , biochemistry , environmental health , chemistry

Patients with end-stage renal disease on hemodialysis have excess cardiovascular disease (CVD) burden with substantially increased CV event rates compared with the general population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research